ALIGOS Therapeutics

  • About
    • Overview
    • Management
    • Board of Directors
  • Science
    • Pipeline
    • Posters & Presentations
  • Patients
    • Chronic HBV Infection
    • MASH
    • Clinical Trials
    • Expanded Access Policy
  • News & Media
    • Press Releases
    • Presentations & Events
  • Investors
    • Overview
    • Stock
      • Stock Quote & Chart
      • Analyst Coverage
    • News & Events
      • News Releases
      • Investor Calendar
    • Financials
      • SEC Filings
      • Quarterly Results
    • Governance
      • Governance Highlights
      • Committee Composition
    • Resources
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers
  • About
    • Overview
    • Management
    • Board of Directors
  • Science
    • Pipeline
    • Posters & Presentations
  • Patients
    • Chronic HBV Infection
    • MASH
    • Clinical Trials
    • Expanded Access Policy
  • News & Media
    • Press Releases
    • Presentations & Events
  • Investors
    • Overview
    • Stock
      • Stock Quote & Chart
      • Analyst Coverage
    • News & Events
      • News Releases
      • Investor Calendar
    • Financials
      • SEC Filings
      • Quarterly Results
    • Governance
      • Governance Highlights
      • Committee Composition
    • Resources
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers

Differentiation of HBV capsid assembly modulators based on stabilization of core protein oligomerization and residence time

Preclinical, Publications

Differentiation of HBV capsid assembly modulators based on stabilization of core protein oligomerization and residence time

Preclinical, Publications

CAM-E and CAM-A Compounds Differentially Affect Phosphorylated and Non-Phosphorylated Hepatitis B Core Protein In Vitro

Preclinical, Publications

Lead Optimization and Selection of a Potential Best-in-Class HBV ASO

Preclinical, Publications

Two Pre-clinical Short Interfering RNA Molecules Targeting Human HSD17beta13 for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

ALG-055009, Publications

A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG-055009, a novel thyroid hormone receptor beta (THR-β) agonist for metabolic dysfunction-associated steatohepatitis (MASH), in healthy participants

Pevifoscorvir-sodium, Publications

The CAM-E ALG-001075 potently reduces HBV cccDNA in preclinical experiments

Preclinical, Publications

Antisense oligonucleotide-based strategy to target hepatitis delta virus infections

Preclinical, Publications

A Syrian hamster model of persistent HDV infection

Preclinical, Publications

Differential impact of CAM-E and CAM-A on hepatitis B core protein phosphorylation states in vitro

Pevifoscorvir-sodium, Publications

Capsid assembly modulators bind and directly target HBeAg

US OFFICE
1 Corporate Dr., 2nd Floor
South San Francisco, CA 94080

EU OFFICE
Gaston Geenslaan 1 / (Building 3)
3001 Leuven, Belgium

CHINA OFFICE
Unit 3212, Building A, No. 100, Zunyi Road, Changning District, Shanghai, People’s Republic of China, 200051

FOLLOW US

info@aligos.com

© Aligos Therapeutics 2026

  • Privacy Policy
  • Terms of Service
MENU
  • About
    • Overview
    • Management
    • Board of Directors
  • Science
    • Pipeline
    • Posters & Presentations
  • Patients
    • Chronic HBV Infection
    • MASH
    • Clinical Trials
    • Expanded Access Policy
  • News & Media
    • Press Releases
    • Presentations & Events
  • Investors
    • Overview
    • Stock
      • Stock Quote & Chart
      • Analyst Coverage
    • News & Events
      • News Releases
      • Investor Calendar
    • Financials
      • SEC Filings
      • Quarterly Results
    • Governance
      • Governance Highlights
      • Committee Composition
    • Resources
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers